AVEO Oncology Reports Results of Fotivda (tivozanib) in P-III TIVO-3 Study for Refractory Advanced or Metastatic Renal Cell Carcinoma (RCC)
Shots:
- The P-III TIVO-3 study involves assessing of Fotivda (tivozanib) vs sorafenib in 350 patients with refractory advanced or metastatic renal cell carcinoma (RCC)
- P-III TIVO-3 results: 44% improvement in mPFS; 26% reduction in the risk of progression or death; mPFS (5.6 vs 3.9 mos.); ORR (18% vs 8%)- presented at ASCO Genitourinary Cancers Symposium- 2019
- FOTIVDA (tivozanib- qd- PO) is a VEGF tyrosine kinase inhibitor (TKI) targeted & approved in EU for RCC and is evaluated in P-II in combination with nivolumab (anti PD-1) for RCC
Ref: AVEO Oncology | Image: Pharma Journalist
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com